We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+20.42%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.1B
AUM Growth
+$380M
Cap. Flow
-$843M
Cap. Flow %
-27.17%
Top 10 Hldgs %
37.76%
Holding
82
New
16
Increased
13
Reduced
14
Closed
12
Avg Time Held
2.9 quarters
Top 10 Avg Time Held
2.7 quarters
Top 20 Avg Time Held
2.4 quarters

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$50.7M
2
CGON icon
CG Oncology
CGON
+$46.2M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$42.3M
4
LEGN icon
Legend Biotech
LEGN
+$41.1M
5
TMDX icon
Transmedics
TMDX
+$40.9M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$41.8M
2
LNTH icon
Lantheus
LNTH
+$30.7M
3
DAWN icon
Day One Biopharmaceuticals
DAWN
+$30.6M
4
KROS icon
Keros Therapeutics
KROS
+$22.6M
5
AMGN icon
Amgen
AMGN
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 57.18%
2 Miscellaneous 42.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KNSA icon
26
Kiniksa Pharmaceuticals
KNSA
$6.15B
$27.5M 0.89%
+1,392,716
New +$27.2M
2024 Q1
0 quarters
TMO icon
27
Thermo Fisher Scientific
TMO
$249B
$27.4M 0.88%
47,149
-28,600
-38% -$16M
2023 Q2
3 quarters
RGEN icon
28
Repligen
RGEN
$11.4B
$26.3M 0.85%
142,836
+40,138
+39% +$7.64M
2023 Q2
3 quarters
NVRO icon
29
DELISTED
NEVRO CORP.
NVRO
$25.7M 0.83%
1,776,368
– –
2022 Q4
5 quarters
INSP icon
30
Inspire Medical Systems
INSP
$1.96B
$21.8M 0.7%
101,492
-83,166
-45% -$16.3M
2023 Q3
2 quarters
CGEM icon
31
Cullinan Oncology
CGEM
$870M
$21.1M 0.68%
1,240,865
– –
2023 Q2
3 quarters
TRML icon
32
DELISTED
Tourmaline Bio
TRML
$20.8M 0.67%
906,820
– –
2023 Q4
1 quarter
LXEO icon
33
Lexeo Therapeutics
LXEO
$212M
$20.7M 0.67%
+1,322,277
New +$20.7M
2024 Q1
0 quarters
SYRE icon
34
Spyre Therapeutics
SYRE
$7.35B
$19.5M 0.63%
515,000
– –
2023 Q4
1 quarter
BMRN icon
35
BioMarin Pharmaceuticals
BMRN
$10.7B
$19.1M 0.62%
+218,896
New +$19.6M
2024 Q1
0 quarters
GPCR icon
36
Structure Therapeutics
GPCR
$1.55B
$18.7M 0.6%
435,823
+155,665
+56% +$6.56M
2023 Q4
1 quarter
BCRX icon
37
BioCryst Pharmaceuticals
BCRX
$2.05B
$17.2M 0.55%
3,379,577
-2,338,900
-41% -$13.2M
2023 Q1
4 quarters
ITOS icon
38
DELISTED
iTeos Therapeutics
ITOS
$15.9M 0.51%
+1,162,374
New +$12.7M
2024 Q1
0 quarters
MLYS icon
39
Mineralys Therapeutics
MLYS
$1.84B
$14.8M 0.48%
1,147,154
-876,746
-43% -$10.8M
2023 Q1
4 quarters
ALEC icon
40
Alector
ALEC
$203M
$14.3M 0.46%
2,380,704
-943,604
-28% -$6.17M
2022 Q4
5 quarters
ARQT icon
41
Arcutis Biotherapeutics
ARQT
$3.33B
$12.9M 0.42%
+1,300,000
New +$9.7M
2024 Q1
0 quarters
ELEV icon
42
DELISTED
Elevation Oncology
ELEV
$12.2M 0.39%
+2,377,647
New +$7.7M
2024 Q1
0 quarters
BBIO icon
43
BridgeBio Pharma
BBIO
$12.6B
$10.7M 0.34%
+344,827
New +$11.7M
2024 Q1
0 quarters
IOVA icon
44
Iovance Biotherapeutics
IOVA
$6.5B
$9.78M 0.32%
+660,022
New +$7.68M
2024 Q1
0 quarters
DCPH icon
45
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$9.59M 0.31%
609,643
-559,847
-48% -$8.62M
2022 Q4
5 quarters
OLMA icon
46
Olema Pharmaceuticals
OLMA
$580M
$7.97M 0.26%
+704,344
New +$9.09M
2024 Q1
0 quarters
LUNG icon
47
Pulmonx
LUNG
$76M
$6.98M 0.22%
752,541
-35,413
-4% -$415K
2022 Q4
5 quarters
DBVT icon
48
DBV Technologies S.A. American Depositary Shares
DBVT
$562M
$5.93M 0.19%
784,329
– –
2022 Q4
5 quarters
OM icon
49
Outset Medical
OM
$72.4M
$5.33M 0.17%
160,028
– –
2022 Q4
5 quarters
ADPT icon
50
Adaptive Biotechnologies
ADPT
$4.1B
$4.36M 0.14%
1,357,490
– –
2023 Q1
4 quarters
1
2
3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q1 2024 Portfolio in Review

As of Q1 2024, Braidwell held 82 positions worth $3.1B, up 14% from $2.72B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Braidwell withdrew a net $843M in Q1 2024, closing 12 positions and reducing 14 holdings. Its most notable exit was Immunocore, an estimated $41.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 49% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in CG Oncology worth $49.6M.

  • Braidwell's largest Q1 2024 buy was CG Oncology: 1,130,235 shares worth $49.6M.
  • Braidwell added most to Apogee Therapeutics in Q1 2024, an estimated $50.7M increase.
  • Braidwell's biggest Q1 2024 reduction was Day One Biopharmaceuticals, cutting an estimated $30.6M.
  • Braidwell fully exited Immunocore in Q1 2024, selling an estimated $41.8M.
  • Braidwell's ten largest holdings make up 38% of its $3.1B portfolio in Q1 2024.
  • Braidwell opened 16 new positions and closed 12 in Q1 2024.
  • Braidwell's portfolio value rose 14% quarter-over-quarter to $3.1B.

Based on Braidwell's 13F filing for Q1 2024, filed 15 May 2024.